Ngoc-Minh Vuong

Ngoc-Minh Vuong

Auto-generated profile, based on publicly available information

Ngoc-Minh Vuong

Department of Adult Cardiac Surgery, University Medical Center Ho Chi Minh City, Ho Chi Minh, Vietnam

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2023 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
TPThuan Q. Phan
Thuan Q. Phan
CPChuong T. V. Pham
Chuong T. V. Pham
Vinh Duc An BuiVinh Duc An Bui
Vinh Duc An Bui
THThang D. Ho
Thang D. Ho
TLThao N. Le
Thao N. Le
DNDinh Hoang Nguyen
Dinh Hoang Nguyen
Background: Cardiac papillary fibroelastomas are rare, accounting for approximately 10% of all cardiac tumors, with 44% of cases located on the aortic valve and only 15% of cases located on the tricuspid valve. However, the optimal management of papillary fibroelastomas remains varied. Case presentation: We present two successful instances of treating heart valve papillary fibroelastomas through minimally invasive surgery. These cases involved heart valve papillary fibroelastomas located in two common sites: the aortic valve on the left heart, which was accessed via an upper hemi-sternotomy, and the tricuspid valve on the right heart, which was accessed via beating heart total thoracoscopy. Conclusion: The article consistently demonstrates the effectiveness of a minimally invasive surgical approach in managing heart valve papillary fibroelastomas. This study provides further evidence by presenting two cases of heart valve papillary fibroelastomas - one on the aortic valve and the other on the tricuspid valve - that were successfully treated using this approach, resulting in favorable outcomes.

16 July 2024 in Radiology Case Reports
Verified
Journal Article
Open access
NVNgoc-Minh Vuong
Ngoc-Minh Vuong
Vinh Duc An BuiVinh Duc An Bui
Vinh Duc An Bui
DNDuy Thanh Nguyen
Duy Thanh Nguyen
DNDang Nguyen
Dang Nguyen
Nityanand JainNityanand Jain
Nityanand Jain
LTLuan Minh Bao Tran
Luan Minh Bao Tran
Spontaneous isolated superior mesenteric artery dissection (SISMAD) is a rare cause of acute abdominal pain, but could potentially be fatal to patients, and should be recognized soon in the emergency department after excluding other common causes. Computed tomography (CT) is the modality of choice for initial diagnosis and follow-up. Currently there is no evidence-based guidelines for managing SISMAD. A 58-year-old man being suspected of a mesenteric artery dissection was referred to our emergergy department. The patient was monitored, treated conservatively with anticoagulant and discharged after 3 days. Follow-up CT scans at 6 month, 1 year and 1 year and a half post discharge showed a partially occluded false lumen, the diameter of true lumen had increased in size and no signs of bowel ischemia. SISMAD should be considered as part of differential diagnoses when patients in their fifth to seventh decades of life present with acute abdominal pain. Treatment includes conservative management, percutaneous endovascular interventions, or surgery, but most patients can be managed conservatively.

20 May 2020 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
VEVirginia Espina
Virginia Espina
NVNgoc Vuong
Ngoc Vuong
ALAlessandra Luchini
Alessandra Luchini
CMClaudius Mueller
Claudius Mueller
DMDenitra S Mack
Denitra S Mack
RHRichard Hoefer
Richard Hoefer
E15533 Background: Biomarker identification for early breast cancer diagnosis is confounded by comparing healthy control patients to patients undergoing surgical procedures and stress of a potential cancer diagnosis. We implemented a clinical research protocol that combines biomarker harvesting and identification with Breast Imaging-Reporting and Data System (BIRADS) results, within a cohort of women with a suspicious mammogram who donated samples prior to biopsy. The primary goals were to discover candidate novel plasma markers for stage I breast cancer versus benign lesions, and validate the markers by mass spectrometry and immunohistochemistry. Methods: 150 women found on screening mammography to have a BIRADS IV or V mammographic abnormality were enrolled in the IRB approved study, with one year follow-up. After informed consent, serum, plasma, and saliva specimens were obtained and frozen. The patient underwent image guided biopsy of the mammographic abnormality. Hydrogel nanoparticles were used to harvest and concentrate low abundance protein biomarkers from plasma. Proteins were identified by mass spectrometry. The BIRADS score and biopsy outcome were blinded to the laboratory researchers. Results: 37/150 women (median age 64, 73% ER+, 70% PR+) were diagnosed with biopsy-proven breast cancer. 15/37 had a family history of breast cancer. Within the context of stress of an abnormal mammogram and invasive biopsy, we identified 5478 plasma peptides. A model to predict endpoints that discriminate cancer vs no cancer was developed using cross-validation and lasso shrinkage method. The best fit multi-analyte ROC/AUC model of peptide spectral matches revealed 10 candidate peptides, including PLAA, TRAPPC9, PROS1, DDX41, ANKRD63, EGFLAM (AUC = 0.81), that discriminated cancer versus no cancer. The functional mechanisms of these proteins are calcium metabolism, GPI anchor biosynthesis, neural-immune crosstalk, DNA repair, and ubiquitin-mediated protein trafficking. Conclusions: Molecular profiling of blood can potentially complement imaging to improve diagnostic specificity in the setting of a suspicious mammogram. This unique trial design, enhanced by nanotechnology protein harvesting, identified potential novel cancer biomarkers in the presence of a suspicious mammogram. A confirmation trial is underway.

3 December 2024 in Radiology Case Reports
Verified
Journal Article
Open access
LTLuan Minh Bao Tran
Luan Minh Bao Tran
DDDuc-Minh Do
Duc-Minh Do
TNTruong Hung Nguyen
Truong Hung Nguyen
NVNgoc-Minh Vuong
Ngoc-Minh Vuong
Triple primary malignancies are rare, involving the occurrence of three distinct, unrelated cancers in a single patient, requiring a personalized, multidisciplinary treatment approach. A 69-year-old male was diagnosed with dermatofibrosarcoma protuberans (DFSP), lung adenocarcinoma, and papillary thyroid carcinoma. After amputation for DFSP, following staging and genetic evaluation, a multidisciplinary tumor board designed a tailored treatment plan, adjuvant chemotherapy for lung adenocarcinoma while monitor regularly the thyroid carcinoma via ultrasound. This case highlights the extreme rarity of this triple primary cancers combination and emphasizes the need for individualized treatment planning. Each cancer's unique characteristics, prognosis, and potential interactions must be considered, alongside the patient's overall health and treatment tolerability, to optimize outcomes in such complex cases.

31 March 2024 in MedPharmRes
Verified
Journal Article
Open access
PDF file
Vinh Duc An BuiVinh Duc An Bui
Vinh Duc An Bui
DNDinh Hoang Nguyen
Dinh Hoang Nguyen
CPChuong Tran Viet Pham
Chuong Tran Viet Pham
TPThuan Quang Phan
Thuan Quang Phan
TNThanh Van Thai Nguyen
Thanh Van Thai Nguyen
NNNam Hoai Nguyen
Nam Hoai Nguyen
MedPharmRes is owned by the University of Medicine and Pharmacy at Ho Chi Minh City and published under Open Access arrangement. MedPharmRes publishes quarterly and covers all fields in medicine, public health, epidemiology, and pharmacy, including drug synthesis and delivery and health and medical education research, in an attempt to bridge the gaps between healthcare and clinical specialization. The journal’s publication criteria are based on the accuracy of the research methodology and high ethical standards.